Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced or Metastatic Solid Tumors
Shots:
- The P-I dose-escalation study will assess the safety- tolerability- and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck- gastric and esophageal cancers- and other tumor types
- The focus of the study is to determine the maximum tolerated dose and recommended dose of DS-1055 for further study and is expected to enroll ~40 patients across the US and Japan. The company will integrate novel technologies with expertise in Ab biology to develop clinical candidates
- DS-1055 is a mAb designed to target GARP and to promote antitumor immunity through the depletion of GARP positive Tregs
Ref: Daiichi Sankyo | Image: Medical Dialogues
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com